Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global T-Cell therapy Market, by End User
1.4.2 Global T-Cell therapy Market, by Indication
1.4.3 Global T-Cell therapy Market, by Therapy Type
1.4.4 Global T-Cell therapy Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.2.5 Trials and Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Sep – 2023, May) Leading Players
Chapter 4. Global T-Cell therapy Market by End User
4.1 Global Hospitals Market by Region
4.2 Global Cancer Treatment Centers Market by Region
Chapter 5. Global T-Cell therapy Market by Indication
5.1 Global Lymphoma Market by Region
5.2 Global Acute Lymphocytic Leukemia Market by Region
5.3 Global Others Market by Region
Chapter 6. Global T-Cell therapy Market by Therapy Type
6.1 Global CAR T-Cell Therapy Market by Region
6.2 Global T-Cell therapy Market by CAR T-Cell Therapy Type
6.2.1 Global Axicabtagene Ciloleucel Market by Region
6.2.2 Global Tisagenlecleucel Market by Region
6.2.3 Global Brexucabtagene Autoleucel Market by Region
6.2.4 Global Others Market by Region
6.3 Global T-Cell Receptor (TCR)-Based Market by Region
Chapter 7. Global T-Cell therapy Market by Region
7.1 North America T-Cell therapy Market
7.1.1 North America T-Cell therapy Market by End User
7.1.1.1 North America Hospitals Market by Country
7.1.1.2 North America Cancer Treatment Centers Market by Country
7.1.2 North America T-Cell therapy Market by Indication
7.1.2.1 North America Lymphoma Market by Country
7.1.2.2 North America Acute Lymphocytic Leukemia Market by Country
7.1.2.3 North America Others Market by Country
7.1.3 North America T-Cell therapy Market by Therapy Type
7.1.3.1 North America CAR T-Cell Therapy Market by Country
7.1.3.2 North America T-Cell therapy Market by CAR T-Cell Therapy Type
7.1.3.2.1 North America Axicabtagene Ciloleucel Market by Country
7.1.3.2.2 North America Tisagenlecleucel Market by Country
7.1.3.2.3 North America Brexucabtagene Autoleucel Market by Country
7.1.3.2.4 North America Others Market by Country
7.1.3.3 North America T-Cell Receptor (TCR)-Based Market by Country
7.1.4 North America T-Cell therapy Market by Country
7.1.4.1 US T-Cell therapy Market
7.1.4.1.1 US T-Cell therapy Market by End User
7.1.4.1.2 US T-Cell therapy Market by Indication
7.1.4.1.3 US T-Cell therapy Market by Therapy Type
7.1.4.2 Canada T-Cell therapy Market
7.1.4.2.1 Canada T-Cell therapy Market by End User
7.1.4.2.2 Canada T-Cell therapy Market by Indication
7.1.4.2.3 Canada T-Cell therapy Market by Therapy Type
7.1.4.3 Mexico T-Cell therapy Market
7.1.4.3.1 Mexico T-Cell therapy Market by End User
7.1.4.3.2 Mexico T-Cell therapy Market by Indication
7.1.4.3.3 Mexico T-Cell therapy Market by Therapy Type
7.1.4.4 Rest of North America T-Cell therapy Market
7.1.4.4.1 Rest of North America T-Cell therapy Market by End User
7.1.4.4.2 Rest of North America T-Cell therapy Market by Indication
7.1.4.4.3 Rest of North America T-Cell therapy Market by Therapy Type
7.2 Europe T-Cell therapy Market
7.2.1 Europe T-Cell therapy Market by End User
7.2.1.1 Europe Hospitals Market by Country
7.2.1.2 Europe Cancer Treatment Centers Market by Country
7.2.2 Europe T-Cell therapy Market by Indication
7.2.2.1 Europe Lymphoma Market by Country
7.2.2.2 Europe Acute Lymphocytic Leukemia Market by Country
7.2.2.3 Europe Others Market by Country
7.2.3 Europe T-Cell therapy Market by Therapy Type
7.2.3.1 Europe CAR T-Cell Therapy Market by Country
7.2.3.2 Europe T-Cell therapy Market by CAR T-Cell Therapy Type
7.2.3.2.1 Europe Axicabtagene Ciloleucel Market by Country
7.2.3.2.2 Europe Tisagenlecleucel Market by Country
7.2.3.2.3 Europe Brexucabtagene Autoleucel Market by Country
7.2.3.2.4 Europe Others Market by Country
7.2.3.3 Europe T-Cell Receptor (TCR)-Based Market by Country
7.2.4 Europe T-Cell therapy Market by Country
7.2.4.1 Germany T-Cell therapy Market
7.2.4.1.1 Germany T-Cell therapy Market by End User
7.2.4.1.2 Germany T-Cell therapy Market by Indication
7.2.4.1.3 Germany T-Cell therapy Market by Therapy Type
7.2.4.2 UK T-Cell therapy Market
7.2.4.2.1 UK T-Cell therapy Market by End User
7.2.4.2.2 UK T-Cell therapy Market by Indication
7.2.4.2.3 UK T-Cell therapy Market by Therapy Type
7.2.4.3 France T-Cell therapy Market
7.2.4.3.1 France T-Cell therapy Market by End User
7.2.4.3.2 France T-Cell therapy Market by Indication
7.2.4.3.3 France T-Cell therapy Market by Therapy Type
7.2.4.4 Russia T-Cell therapy Market
7.2.4.4.1 Russia T-Cell therapy Market by End User
7.2.4.4.2 Russia T-Cell therapy Market by Indication
7.2.4.4.3 Russia T-Cell therapy Market by Therapy Type
7.2.4.5 Spain T-Cell therapy Market
7.2.4.5.1 Spain T-Cell therapy Market by End User
7.2.4.5.2 Spain T-Cell therapy Market by Indication
7.2.4.5.3 Spain T-Cell therapy Market by Therapy Type
7.2.4.6 Italy T-Cell therapy Market
7.2.4.6.1 Italy T-Cell therapy Market by End User
7.2.4.6.2 Italy T-Cell therapy Market by Indication
7.2.4.6.3 Italy T-Cell therapy Market by Therapy Type
7.2.4.7 Rest of Europe T-Cell therapy Market
7.2.4.7.1 Rest of Europe T-Cell therapy Market by End User
7.2.4.7.2 Rest of Europe T-Cell therapy Market by Indication
7.2.4.7.3 Rest of Europe T-Cell therapy Market by Therapy Type
7.3 Asia Pacific T-Cell therapy Market
7.3.1 Asia Pacific T-Cell therapy Market by End User
7.3.1.1 Asia Pacific Hospitals Market by Country
7.3.1.2 Asia Pacific Cancer Treatment Centers Market by Country
7.3.2 Asia Pacific T-Cell therapy Market by Indication
7.3.2.1 Asia Pacific Lymphoma Market by Country
7.3.2.2 Asia Pacific Acute Lymphocytic Leukemia Market by Country
7.3.2.3 Asia Pacific Others Market by Country
7.3.3 Asia Pacific T-Cell therapy Market by Therapy Type
7.3.3.1 Asia Pacific CAR T-Cell Therapy Market by Country
7.3.3.2 Asia Pacific T-Cell therapy Market by CAR T-Cell Therapy Type
7.3.3.2.1 Asia Pacific Axicabtagene Ciloleucel Market by Country
7.3.3.2.2 Asia Pacific Tisagenlecleucel Market by Country
7.3.3.2.3 Asia Pacific Brexucabtagene Autoleucel Market by Country
7.3.3.2.4 Asia Pacific Others Market by Country
7.3.3.3 Asia Pacific T-Cell Receptor (TCR)-Based Market by Country
7.3.4 Asia Pacific T-Cell therapy Market by Country
7.3.4.1 China T-Cell therapy Market
7.3.4.1.1 China T-Cell therapy Market by End User
7.3.4.1.2 China T-Cell therapy Market by Indication
7.3.4.1.3 China T-Cell therapy Market by Therapy Type
7.3.4.2 Japan T-Cell therapy Market
7.3.4.2.1 Japan T-Cell therapy Market by End User
7.3.4.2.2 Japan T-Cell therapy Market by Indication
7.3.4.2.3 Japan T-Cell therapy Market by Therapy Type
7.3.4.3 India T-Cell therapy Market
7.3.4.3.1 India T-Cell therapy Market by End User
7.3.4.3.2 India T-Cell therapy Market by Indication
7.3.4.3.3 India T-Cell therapy Market by Therapy Type
7.3.4.4 South Korea T-Cell therapy Market
7.3.4.4.1 South Korea T-Cell therapy Market by End User
7.3.4.4.2 South Korea T-Cell therapy Market by Indication
7.3.4.4.3 South Korea T-Cell therapy Market by Therapy Type
7.3.4.5 Singapore T-Cell therapy Market
7.3.4.5.1 Singapore T-Cell therapy Market by End User
7.3.4.5.2 Singapore T-Cell therapy Market by Indication
7.3.4.5.3 Singapore T-Cell therapy Market by Therapy Type
7.3.4.6 Malaysia T-Cell therapy Market
7.3.4.6.1 Malaysia T-Cell therapy Market by End User
7.3.4.6.2 Malaysia T-Cell therapy Market by Indication
7.3.4.6.3 Malaysia T-Cell therapy Market by Therapy Type
7.3.4.7 Rest of Asia Pacific T-Cell therapy Market
7.3.4.7.1 Rest of Asia Pacific T-Cell therapy Market by End User
7.3.4.7.2 Rest of Asia Pacific T-Cell therapy Market by Indication
7.3.4.7.3 Rest of Asia Pacific T-Cell therapy Market by Therapy Type
7.4 LAMEA T-Cell therapy Market
7.4.1 LAMEA T-Cell therapy Market by End User
7.4.1.1 LAMEA Hospitals Market by Country
7.4.1.2 LAMEA Cancer Treatment Centers Market by Country
7.4.2 LAMEA T-Cell therapy Market by Indication
7.4.2.1 LAMEA Lymphoma Market by Country
7.4.2.2 LAMEA Acute Lymphocytic Leukemia Market by Country
7.4.2.3 LAMEA Others Market by Country
7.4.3 LAMEA T-Cell therapy Market by Therapy Type
7.4.3.1 LAMEA CAR T-Cell Therapy Market by Country
7.4.3.2 LAMEA T-Cell therapy Market by CAR T-Cell Therapy Type
7.4.3.2.1 LAMEA Axicabtagene Ciloleucel Market by Country
7.4.3.2.2 LAMEA Tisagenlecleucel Market by Country
7.4.3.2.3 LAMEA Brexucabtagene Autoleucel Market by Country
7.4.3.2.4 LAMEA Others Market by Country
7.4.3.3 LAMEA T-Cell Receptor (TCR)-Based Market by Country
7.4.4 LAMEA T-Cell therapy Market by Country
7.4.4.1 Brazil T-Cell therapy Market
7.4.4.1.1 Brazil T-Cell therapy Market by End User
7.4.4.1.2 Brazil T-Cell therapy Market by Indication
7.4.4.1.3 Brazil T-Cell therapy Market by Therapy Type
7.4.4.2 Argentina T-Cell therapy Market
7.4.4.2.1 Argentina T-Cell therapy Market by End User
7.4.4.2.2 Argentina T-Cell therapy Market by Indication
7.4.4.2.3 Argentina T-Cell therapy Market by Therapy Type
7.4.4.3 UAE T-Cell therapy Market
7.4.4.3.1 UAE T-Cell therapy Market by End User
7.4.4.3.2 UAE T-Cell therapy Market by Indication
7.4.4.3.3 UAE T-Cell therapy Market by Therapy Type
7.4.4.4 Saudi Arabia T-Cell therapy Market
7.4.4.4.1 Saudi Arabia T-Cell therapy Market by End User
7.4.4.4.2 Saudi Arabia T-Cell therapy Market by Indication
7.4.4.4.3 Saudi Arabia T-Cell therapy Market by Therapy Type
7.4.4.5 South Africa T-Cell therapy Market
7.4.4.5.1 South Africa T-Cell therapy Market by End User
7.4.4.5.2 South Africa T-Cell therapy Market by Indication
7.4.4.5.3 South Africa T-Cell therapy Market by Therapy Type
7.4.4.6 Nigeria T-Cell therapy Market
7.4.4.6.1 Nigeria T-Cell therapy Market by End User
7.4.4.6.2 Nigeria T-Cell therapy Market by Indication
7.4.4.6.3 Nigeria T-Cell therapy Market by Therapy Type
7.4.4.7 Rest of LAMEA T-Cell therapy Market
7.4.4.7.1 Rest of LAMEA T-Cell therapy Market by End User
7.4.4.7.2 Rest of LAMEA T-Cell therapy Market by Indication
7.4.4.7.3 Rest of LAMEA T-Cell therapy Market by Therapy Type
Chapter 8. Company Profiles
8.1 Merck KGaA
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Johnson & Johnson
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental &Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.3 AbbVie, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Gilead Sciences, Inc.
8.4.1 Company overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expenses
8.4.4 Recent strategies and developments:
8.4.4.1 Partnerships, Collaborations, and Agreements:
8.4.4.2 Acquisition and Mergers:
8.4.4.3 Trials and Approvals:
8.5 Amgen, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Acquisition and Mergers:
8.6 Novartis AG
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Product Launches and Product Expansions:
8.6.5.2 Acquisition and Mergers:
8.6.5.3 Trials and Approvals:
8.7 Sorrento Therapeutics, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.7.5.2 Trials and Approvals:
8.8 Bristol Myers Squibb Company
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.8.5.2 Acquisition and Mergers:
8.8.5.3 Geographical Expansions:
8.8.5.4 Trials and Approvals:
8.9 Pfizer, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional & Segmental Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.9.5.2 Acquisition and Mergers:
8.10. Immunocore Holdings plc
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
8.10.4.2 Trials and Approvals:
Unique Offerings 
